Qiagen Consolidates, Invests $10M in Maryland Facilities | GenomeWeb

NEW YORK (GenomeWeb News) – Qiagen today announced changes to its Maryland operations with the consolidation of three facilities into two and a $10 million investment into the businesses.

As part of the changes, Qiagen will shutter its Gaithersburg manufacturing facility and move it to the company's Germantown site, which will manufacture some of Qiagen's highest volume diagnostics assays, including the digene HC2 HPV Test for cervical cancer prevention.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.